Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 144

Travere Therapeutics, Inc.

TVTXNASDAQEQUITYCurrent

SEC Filing

Filed Sep 16, 2026Accepted Sep 16, 2026, 4:33 PM EDTCIK 1438533Accession 0001950047-26-009577
Share

Company context

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent - that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow. For more information, visit travere.com.

Current securities

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 21, 2026
  2. 4 filingSep 17, 2026
  3. 144 filingSep 17, 2026
  4. 144 filingSep 17, 2026
  5. 144 filingSep 16, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗